search
Back to results

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)

Primary Purpose

Metastatic Breast Cancer

Status
Not yet recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Lasofoxifene in combination with abemaciclib
Fulvestrant in combination with abemaciclib
Sponsored by
Sermonix Pharmaceuticals Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metastatic Breast Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Pre- or postmenopausal women or men. Locally advanced and/or metastatic ER+ breast cancer with radiological or clinical evidence of progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease. No evidence of progression for at least 6 months on an AI/CDKi combination for advanced breast cancer. At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast cancer tissue. Locally advanced or metastatic breast cancer with either measurable (according to RECIST 1.1) or non-measurable lesions. Subjects may have received 1 cytotoxic chemotherapy regimen in the metastatic disease setting prior to study entry, but must have recovered from chemotherapy acute toxicity excluding alopecia and Grade 2 peripheral neuropathy. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 Adequate organ function Able to swallow tablets Brain metastases are allowed only if the following 4 parameters hold: Asymptomatic, Definitively treated (e.g., radiotherapy, surgery), Not requiring steroids up to 4 weeks before study treatment initiation, AND Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI). 10. Able to understand and voluntarily sign a written informed consent before any screening procedures. Exclusion Criteria: Lymphangitic carcinomatosis involving the lung. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy. Visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator. Prior progression of disease on abemaciclib, fulvestrant, or other selective estrogen receptor degrader (SERD) therapy. Subjects with a known hypersensitivity to fulvestrant or to any of the excipients Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1). Known RB1 mutations or deletions that in the opinion of the investigator confer resistance to CDK4/6i. (Screening for RB1 mutation is not required for entry.) History of long QTc (Q-T interval corrected for heart rate) syndrome or a QTc of >480 msec. History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia. Lasofoxifene is not recommended for use in subjects with conditions that place them at increased risk for VTEs (such as severe congestive heart failure [CHF] or prolonged immobilization). On concomitant strong CYP3A4 inhibitors. On strong and moderate CYP3A4 inducers. Any significant co-morbidity that would impact the study or the subject's safety, including subjects with significant malabsorption. Active systemic bacterial or fungal infection (requiring intravenous [IV] antibiotics or antifungals at the time of initiating study treatment). Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery. Positive serum pregnancy test (only if premenopausal). Sexually active premenopausal women and men unwilling to use contraception. History of non-compliance to medical regimens. Unwilling or unable to comply with the protocol. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.

Sites / Locations

  • Mayo Clinic - Scottsdale
  • University of Arizona - Cancer Center
  • California Research Institute
  • Providence Medical Foundation - Santa Rosa, CA
  • Boca Raton Regional Hospital
  • Mayo Clinic - Jacksonville
  • Miami Cancer Institute
  • Miami Cancer Institute Plantation
  • Emory University School of Medicine
  • Norton Cancer Institute
  • Hematology Oncology Clinic
  • Johns Hopkins Kimmel Cancer Center
  • Massachusetts General Hospital
  • Dana-Farber Cancer Institute
  • Henry Ford Health System
  • Cancer and Hematology Centers of Western Michigan
  • Mayo Clinic - Rochester
  • Saint Luke's Cancer Institute
  • Washington University School of Medicine
  • University of Nebraska Medical Center
  • New Jersey Cancer Care, PA
  • Icahn School of Medicine at Mount Sinai
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
  • Duke University Medical Center
  • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)
  • Oklahoma University Health Sciences Center
  • University of Pittsburgh Medical Center
  • Chattanooga Oncology Hematology Care - Tennessee Oncology
  • Vanderbilt University Medical Center
  • Lyndon B. Johnson Hospital
  • Baylor College of Medicine
  • MD Anderson Cancer Center
  • Flinders Medical Centre
  • Blacktown Hospital
  • Concord Repatriation General Hospital
  • Mater Misericordiae Ltd, South Brisbane
  • Cliniques Universitaires Saint-Luc
  • Antwerp University Hospital (UZA)
  • Universitaire Ziekenhuizen Leuven
  • Clinique CHC MontLégia
  • CHU UCL Namur - Site De Sainte-Elisabeth
  • The Ottawa General Hospital
  • Sunnybrook Health Sciences Centre -Bayview Campus
  • Hospital Maisonneuve-Rosemont
  • Hospital Notre Dame du CHUM
  • Lady Davis Institute for Medical Research Jewish General Hospital
  • CIUSSS du Saguenay-Lac-Saint-Jean
  • Masarykuv onkologicky ustav
  • Fakultni nemocnice Hradec Kralove
  • Fakultni nemocnice Olomouc - Oncology clinic
  • Fakultní nemocnice v Motole
  • Service d'Oncologie Medicale - CHRU Besancon
  • Institut Bergonie
  • Centre Francois Baclesse
  • Centre Oscar Lambret
  • Centre Leon Berard
  • Institut Paoli-Calmettes
  • CHU Poitiers - Pole Regional de Cancerologie de Poitiers (PRC)
  • Centre Henri Becquerel
  • Institut de cancerologie Strasbourg Europe (ICANS)
  • Institut Claudius Regaud
  • Universitaetsklinikum Carl Gustav Carus Dresden
  • Universitaetsklinikum Ulm
  • Budapesti Uzsoki Utcai Korhaz
  • Debreceni Egyetem Klinikai Kozpont
  • Rambam Health Care Campus
  • Hadassah Ein-Karem Medical Center
  • Shaare Zedek Medical Center
  • Rabin MC
  • Kaplan Medical Center
  • Tel Aviv Sourasky Medical Center
  • Sheba Medical Center
  • Centro Riferimento Oncologico - Aviano
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
  • Istituto Europeo di Oncologia
  • Humanitas Istituto Clinico Catanese
  • Azienda Ospedaliero-Universitaria di Modena
  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
  • Azienda Ospedaliero Universitaria di Parma
  • Fondazione IRCCS Policlinico San Matteo
  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
  • Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
  • National Cancer Center
  • Asan Medical Center
  • Korea University Anam Hospital
  • Severance Hospital, Yonsei University Health System
  • KO - MED Centra Kliniczne Sp. z o.o., Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej
  • Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii
  • Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Klinika Onkologii Klinicznej
  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie - Oddzial Onkologii Klinicznej z Pododdzialem Dziennym
  • SP ZOZ Szpital Uniwersytecki w Krakowie, Oddzial Onkologii Klinicznej
  • NeuroMed
  • Uniwersytecki Szpital Kliniczny w Poznaniu, Oddzial Chemioterapii
  • Wielkopolskie Centrum Onkologii (WCO) / The Greater Poland Cancer Center
  • Mazowiecki Szpital Onkologiczny
  • Instytut Centrum Zdrowia Matki Polki - Klinika Onkologii
  • Centrul Medical Focus
  • Filantropia Clinical Hospital
  • Radiotherapy Center Cluj
  • Onco Clinic Consult SA
  • Oncology Center Sfantul Nectarie
  • Gral Medical SRL
  • OncoMed Oncology Center
  • Hospital Clinic Barcelona
  • Hospital Universitario Vall d'Hebron
  • Hospital Universitario Reina Sofia
  • Clinica Universidad de Navarra - Madrid
  • Hospital General Universitario Gregorio Maranon
  • Hospital Universitario 12 de Octubre
  • Hospital Universitario de La Princesa
  • Hospital Regional Universitario de Malaga
  • Clinica Universidad de Navarra - Pamplona
  • Instituto Valenciano de Oncologia
  • Changhua Christian Hospital (CCH)
  • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
  • National Cheng Kung University Hospital
  • Tri-Service General Hospital
  • Koo Foundation Sun Yat-Sen Cancer Center
  • National Taiwan University Hospital
  • Linkou Chang Gung Memorial Hospital (CGMHLK)
  • Trakya University Medical Faculty
  • Kocaeli University Faculty of Medicine
  • Ankara University Medical Faculty Medical Oncology Department
  • Uludag University Medical Faculty
  • Liv Hospital Ankara
  • Goztepe Prof. Dr. Suleyman Yalcin City Hospital
  • Medical Point Izmir Hospital
  • Suat Seren Training and Research Hospital
  • West Middlesex University Hospital
  • Leeds Teaching Hospitals NHS Trust
  • The Christie NHS Foundation Trust
  • Nottingham City Hospital
  • Lancashire Teaching Hospitals

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Treatment

Reference Therapy

Arm Description

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

Outcomes

Primary Outcome Measures

Progression free survival (PFS)
PFS is defined as the time from the date of randomization [Visit 0 (Day 1)] to the earliest date of first documented progression or death due to any cause.

Secondary Outcome Measures

Objective response rate (ORR)
ORR is defined as the percentage of subjects with measurable disease at baseline whose best overall response is either a confirmed CR or a confirmed PR according to RECIST 1.1.
Overall survival (OS)
Overall survival is defined as time from the date of Visit 0 (Day 1) to death due to any cause.
Clinical benefit rate (CBR)
CBR is defined as the percentage of subjects with best overall response of confirmed CR, confirmed PR, or stable disease (SD) with a duration of 24 weeks or longer according to RECIST 1.1. As used in this calculation, stable disease is defined as stable disease in those subjects with measurable disease plus nonPR/non progressive disease (PD) in subjects with non-measurable disease.
Duration of response (DoR) in subjects with an objective response
DoR is from the date of first documented confirmed response (CR or PR) to the date of first documented progression of disease or death due to any cause, whichever is earlier.
Time to response (TTR) in subjects with an objective response
TTR is from the date of randomization to the date of first documented confirmed response (CR or PR).
Time to cytotoxic chemotherapy
From the date of randomization to the date of first documented use of cytotoxic chemotherapy.
Quality of Life (QoL) evaluated using the Functional Assessment of Cancer Therapy-Breast Cancer-Endocrine Subscale (FACT B-ES)
Scale ranges from 'Not at all' to 'Very much'
Incidence of Adverse Events (AEs) and Serious AEs
The type, severity (graded by Common Terminology Criteria for Adverse Events [CTCAE version 5.0]), course, duration, seriousness, and relationship to study treatment will be assessed at each visit

Full Information

First Posted
January 13, 2023
Last Updated
October 9, 2023
Sponsor
Sermonix Pharmaceuticals Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05696626
Brief Title
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Acronym
ELAINEIII
Official Title
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
June 2025 (Anticipated)
Study Completion Date
June 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sermonix Pharmaceuticals Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metastatic Breast Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
open label, randomized, parallel-group, multicenter study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.
Arm Title
Reference Therapy
Arm Type
Active Comparator
Arm Description
Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.
Intervention Type
Drug
Intervention Name(s)
Lasofoxifene in combination with abemaciclib
Intervention Description
5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
Intervention Type
Drug
Intervention Name(s)
Fulvestrant in combination with abemaciclib
Intervention Description
Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
Primary Outcome Measure Information:
Title
Progression free survival (PFS)
Description
PFS is defined as the time from the date of randomization [Visit 0 (Day 1)] to the earliest date of first documented progression or death due to any cause.
Time Frame
Within approximately 3 years
Secondary Outcome Measure Information:
Title
Objective response rate (ORR)
Description
ORR is defined as the percentage of subjects with measurable disease at baseline whose best overall response is either a confirmed CR or a confirmed PR according to RECIST 1.1.
Time Frame
Within approximately 3 years
Title
Overall survival (OS)
Description
Overall survival is defined as time from the date of Visit 0 (Day 1) to death due to any cause.
Time Frame
Within approximately 3 years
Title
Clinical benefit rate (CBR)
Description
CBR is defined as the percentage of subjects with best overall response of confirmed CR, confirmed PR, or stable disease (SD) with a duration of 24 weeks or longer according to RECIST 1.1. As used in this calculation, stable disease is defined as stable disease in those subjects with measurable disease plus nonPR/non progressive disease (PD) in subjects with non-measurable disease.
Time Frame
Within approximately 3 years
Title
Duration of response (DoR) in subjects with an objective response
Description
DoR is from the date of first documented confirmed response (CR or PR) to the date of first documented progression of disease or death due to any cause, whichever is earlier.
Time Frame
Within approximately 3 years
Title
Time to response (TTR) in subjects with an objective response
Description
TTR is from the date of randomization to the date of first documented confirmed response (CR or PR).
Time Frame
Within approximately 3 years
Title
Time to cytotoxic chemotherapy
Description
From the date of randomization to the date of first documented use of cytotoxic chemotherapy.
Time Frame
Within approximately 3 years
Title
Quality of Life (QoL) evaluated using the Functional Assessment of Cancer Therapy-Breast Cancer-Endocrine Subscale (FACT B-ES)
Description
Scale ranges from 'Not at all' to 'Very much'
Time Frame
Within approximately 3 years
Title
Incidence of Adverse Events (AEs) and Serious AEs
Description
The type, severity (graded by Common Terminology Criteria for Adverse Events [CTCAE version 5.0]), course, duration, seriousness, and relationship to study treatment will be assessed at each visit
Time Frame
Within approximately 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pre- or postmenopausal women or men. Locally advanced and/or metastatic ER+ breast cancer with radiological or clinical evidence of progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease. No evidence of progression for at least 6 months on an AI/CDKi combination for advanced breast cancer. At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast cancer tissue. Locally advanced or metastatic breast cancer with either measurable (according to RECIST 1.1) or non-measurable lesions. Subjects may have received 1 cytotoxic chemotherapy regimen in the metastatic disease setting prior to study entry, but must have recovered from chemotherapy acute toxicity excluding alopecia and Grade 2 peripheral neuropathy. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 Adequate organ function Able to swallow tablets Brain metastases are allowed only if the following 4 parameters hold: Asymptomatic, Definitively treated (e.g., radiotherapy, surgery), Not requiring steroids up to 4 weeks before study treatment initiation, AND Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI). 10. Able to understand and voluntarily sign a written informed consent before any screening procedures. Exclusion Criteria: Lymphangitic carcinomatosis involving the lung. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy. Visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator. Prior progression of disease on abemaciclib, fulvestrant, or other selective estrogen receptor degrader (SERD) therapy. Subjects with a known hypersensitivity to fulvestrant or to any of the excipients Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1). Known RB1 mutations or deletions that in the opinion of the investigator confer resistance to CDK4/6i. (Screening for RB1 mutation is not required for entry.) History of long QTc (Q-T interval corrected for heart rate) syndrome or a QTc of >480 msec. History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia. Lasofoxifene is not recommended for use in subjects with conditions that place them at increased risk for VTEs (such as severe congestive heart failure [CHF] or prolonged immobilization). On concomitant strong CYP3A4 inhibitors. On strong and moderate CYP3A4 inducers. Any significant co-morbidity that would impact the study or the subject's safety, including subjects with significant malabsorption. Active systemic bacterial or fungal infection (requiring intravenous [IV] antibiotics or antifungals at the time of initiating study treatment). Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery. Positive serum pregnancy test (only if premenopausal). Sexually active premenopausal women and men unwilling to use contraception. History of non-compliance to medical regimens. Unwilling or unable to comply with the protocol. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sermonix Pharmaceuticals Study Inquiry
Phone
614-864-4919
Email
info@sermonixpharma.com
Facility Information:
Facility Name
Mayo Clinic - Scottsdale
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lida Mina
Email
mina.lida@mayo.edu
Facility Name
University of Arizona - Cancer Center
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85719
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Segar
Phone
520-626-8096
Email
segar@arizona.edu
Facility Name
California Research Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ghassan Al-Jazayrly
Email
pi@caresinst.com
Facility Name
Providence Medical Foundation - Santa Rosa, CA
City
Santa Rosa
State/Province
California
ZIP/Postal Code
95403
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jarrod Holmes
Email
jarrod.holmes@stjoe.org
Facility Name
Boca Raton Regional Hospital
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angelina The
Email
athe@baptisthealth.net
Facility Name
Mayo Clinic - Jacksonville
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pooja Advani
Email
advani.pooja@mayo.edu
Facility Name
Miami Cancer Institute
City
Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grace Wang
Email
gracew@baptisthealth.net
Facility Name
Miami Cancer Institute Plantation
City
Plantation
State/Province
Florida
ZIP/Postal Code
33324
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grace Wang
Email
gracew@baptisthealth.net
Facility Name
Emory University School of Medicine
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jane Meisel
Email
jane.l.meisel@emory.edu
Facility Name
Norton Cancer Institute
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laila Agrawal
Email
laila.agrawal@nortonhealthcare.org
Facility Name
Hematology Oncology Clinic
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70809
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gerald Miletello
Facility Name
Johns Hopkins Kimmel Cancer Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21231
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Tao
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Seth Wander
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah Sammons
Email
sarahl_sammons@dfci.harvard.edu
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marian Girgis
Facility Name
Cancer and Hematology Centers of Western Michigan
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49503
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amy Vander Woude
Email
avanderwoude@gmail.com
Facility Name
Mayo Clinic - Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthew Goetz,
Email
Goetz.Matthew@mayo.edu
Facility Name
Saint Luke's Cancer Institute
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Timothy Pluard
Phone
816-932-3300
Email
tpluard@saint-lukes.org
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nusayba Bagegni
Email
nbagegni@wustl.edu
Facility Name
University of Nebraska Medical Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68198
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amulya Yellala
Email
amulya.yellala@unmc.edu
Facility Name
New Jersey Cancer Care, PA
City
Belleville
State/Province
New Jersey
ZIP/Postal Code
07109
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James Orsini
Phone
973-751-8880
Ext
269
Email
jmo@njcancercare.com
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amy Tiersten
Facility Name
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sherry Shen
Email
shens1@mskcc.org
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rani Bansal
Email
rani.bansal@duke.edu
Facility Name
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)
City
Columbus
State/Province
Ohio
ZIP/Postal Code
42112
Country
United States
Facility Name
Oklahoma University Health Sciences Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wajeeha Razaq
Phone
405-271-4022
Email
wajeeha.usa@gmail.com
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adam Brufsky
Phone
412-641-4530
Email
brufskyam@upmc.edu
Facility Name
Chattanooga Oncology Hematology Care - Tennessee Oncology
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37404
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brooke Daniel
Phone
423-698-1844
Email
brd@cohaonline.com
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37204
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Kennedy
Email
laura.kennedy@vumc.org
Facility Name
Lyndon B. Johnson Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77026
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Senthil Damodaran
Email
SDamodaran@mdanderson.org
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ahmed Elkhanany
Email
Ahmed.Elkhanany@bcm.edu
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Senthil Damodaran
Email
SDamodaran@mdanderson.org
Facility Name
Flinders Medical Centre
City
Bedford Park
Country
Australia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Mislang
Email
anna.mislang@sa.gov.au
Facility Name
Blacktown Hospital
City
Blacktown
Country
Australia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Man
Email
jennifer.man@health.nsw.gov.au
Facility Name
Concord Repatriation General Hospital
City
Concord
Country
Australia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Belinda Kiely
Phone
+61 02 9767 6354
Email
belinda.kiely@health.nsw.gov.au
Facility Name
Mater Misericordiae Ltd, South Brisbane
City
South Brisbane
Country
Australia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kathryn Middleton
Phone
+61 07 31632531
Email
kathryn.middleton@mater.org.au
Facility Name
Cliniques Universitaires Saint-Luc
City
Brussels
Country
Belgium
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francois Duhoux
Phone
+32 2 764 51 06
Email
francois.duhoux@saintluc.uclouvain.be
Facility Name
Antwerp University Hospital (UZA)
City
Edegem
Country
Belgium
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sevilay Altintas
Phone
+32 3 821 49 73
Email
sevilay.altintas@uza.be
Facility Name
Universitaire Ziekenhuizen Leuven
City
Leuven
Country
Belgium
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrick Neven
Email
patrick.neven@uzleuven.be
Facility Name
Clinique CHC MontLégia
City
Liège
Country
Belgium
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Marechal
Phone
+32 4 355 42 13
Email
stephanie.marechal@chc.be
Facility Name
CHU UCL Namur - Site De Sainte-Elisabeth
City
Namur
Country
Belgium
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Donatienne Taylor
Phone
003281720524
Email
donatienne.taylor@chuuclnamur.uclouvain.be; donatienne.taylor@uclouvain.be
Facility Name
The Ottawa General Hospital
City
Ottawa
State/Province
Ontario
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rakesh Goel
Phone
(613) 737-7700
Ext
70171
Email
rgoel@ottawahospital.on.ca
Facility Name
Sunnybrook Health Sciences Centre -Bayview Campus
City
Toronto
State/Province
Ontario
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ellen Warner
Phone
416-480-4617
Email
ellen.warner@sunnybrook.ca
Facility Name
Hospital Maisonneuve-Rosemont
City
Montréal
State/Province
Quebec
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonathan Noujaim
Facility Name
Hospital Notre Dame du CHUM
City
Montréal
State/Province
Quebec
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Pierre Ayoub
Facility Name
Lady Davis Institute for Medical Research Jewish General Hospital
City
Montréal
State/Province
Quebec
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Parvaneh Fallah
Email
parvaneh.fallah@mail.mcgill.ca
Facility Name
CIUSSS du Saguenay-Lac-Saint-Jean
City
Saguenay
State/Province
Quebec
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jose Guimares
Facility Name
Masarykuv onkologicky ustav
City
Brno
Country
Czechia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marketa Palacova
Phone
+420 543 136 107
Email
palacova@mou.cz
Facility Name
Fakultni nemocnice Hradec Kralove
City
Hradec Králové
Country
Czechia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adam Paulik
Phone
+420 495 834 647
Email
adam.paulik@fnhk.cz
Facility Name
Fakultni nemocnice Olomouc - Oncology clinic
City
Olomouc
Country
Czechia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bohuslav Melichar
Phone
+420 588 444 288
Email
bohuslav.melichar@fnol.cz
Facility Name
Fakultní nemocnice v Motole
City
Praha 5
Country
Czechia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vlastimila Cmejlova
Email
vlastimila.cmejlova@fnmotol.cz
Facility Name
Service d'Oncologie Medicale - CHRU Besancon
City
Besançon
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Mansi
Facility Name
Institut Bergonie
City
Bordeaux
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marc Debled
Phone
+33 (0)5 56 33 04 77
Email
M.Debled@bordeaux.unicancer.fr
Facility Name
Centre Francois Baclesse
City
CAEN Cedex 05
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
George Emile
Email
g.emile@baclesse.unicancer.fr
Facility Name
Centre Oscar Lambret
City
Lille
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charlotte Bellier
Phone
+33 (0)3.20.29.59.59
Email
investigation@o-lambret.fr;c-bellier@o-lambret.fr
Facility Name
Centre Leon Berard
City
Lyon
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Bachelot
Phone
+33 4 78 78 26 54
Email
thomas.bachelot@lyon.unicancer.fr
Facility Name
Institut Paoli-Calmettes
City
Marseille
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandre Tassin de Nonneville
Phone
+44491223789
Email
tassindenonnevillea@ipc.unicancer.fr
Facility Name
CHU Poitiers - Pole Regional de Cancerologie de Poitiers (PRC)
City
Poitiers
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas Isambert
Email
nicolas.isambert@chu-poitiers.fr
Facility Name
Centre Henri Becquerel
City
Rouen
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marianne Leheurteur
Email
marianne.leheurteur@chb.unicancer.fr
Facility Name
Institut de cancerologie Strasbourg Europe (ICANS)
City
Strasbourg
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe Trensz
Phone
0368767231
Email
p.trensz@icans.eu
Facility Name
Institut Claudius Regaud
City
Toulouse
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florence Dalenc
Phone
(+33) 5 31 15 51 22
Email
dalenc.florence@iuct-oncopole.fr
Facility Name
Universitaetsklinikum Carl Gustav Carus Dresden
City
Dresden
Country
Germany
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pauline Wimberger
Phone
+49 (0)351 458-6728
Email
pauline.wimberger@uniklinikum.dresden.de
Facility Name
Universitaetsklinikum Ulm
City
Ulm
Country
Germany
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brigitte Rack
Phone
+4973150058523
Email
brigitte.rack@uniklinik-ulm.de;studienzentrale.ufk@uniklinik-ulm.de
Facility Name
Budapesti Uzsoki Utcai Korhaz
City
Budapest
Country
Hungary
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nora Bittner
Phone
336-30-338-4465
Email
nora_bittner@yahoo.ca
Facility Name
Debreceni Egyetem Klinikai Kozpont
City
Debrecen
Country
Hungary
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Arkosy
Phone
003652255840
Email
arkosy.peter@med.unideb.hu
Facility Name
Rambam Health Care Campus
City
Haifa
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ayelet Shai
Facility Name
Hadassah Ein-Karem Medical Center
City
Jerusalem
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shani Paluch-Shimon
Email
shanipal@hadassah.org.il
Facility Name
Shaare Zedek Medical Center
City
Jerusalem
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hadar Goldvaser
Email
hadargo@szmc.org.il
Facility Name
Rabin MC
City
Petach Tikva
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rinat Yerushalmi
Email
rinaty@clalit.org.il
Facility Name
Kaplan Medical Center
City
Reẖovot
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ella Evron
Email
allaev@clalit.org.il
Facility Name
Tel Aviv Sourasky Medical Center
City
Tel Aviv
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amir Sonnenblick
Email
amirson@tlvmc.gov.il
Facility Name
Sheba Medical Center
City
Tel HaShomer
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Einav Nili Gal-Yam
Phone
+972-3-5302243
Email
Einav.NiliGal-Yam@sheba.health.gov.il
Facility Name
Centro Riferimento Oncologico - Aviano
City
Aviano
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lorenzo Gerratana
Phone
(+39) 0434 659254
Email
lgerratana@gmail.com; lorenzo.gerratana@cro.it
Facility Name
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
City
Meldola
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ugo De Giorgi
Phone
0039 0543 739100
Email
ugo.degiorgi@irst.emr.it
Facility Name
Istituto Europeo di Oncologia
City
Milano
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marco Angelo Colleoni
Phone
02-57489.970
Email
marco.colleoni@ieo.it; emilia.montagna@ieo.it
Facility Name
Humanitas Istituto Clinico Catanese
City
Misterbianco
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Vita Sanò
Phone
09573390197
Email
maria.vita_sano@ccocatania.it
Facility Name
Azienda Ospedaliero-Universitaria di Modena
City
Modena
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luca Moscetti
Phone
+390594223244
Email
moscetti.luca@aou.mo.it
Facility Name
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
City
Napoli
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelino De Laurentiis
Phone
+3908117770442
Email
delauren@breastunit.org; m.delaurentiis@istitutotumori.na.it
Facility Name
Azienda Ospedaliero Universitaria di Parma
City
Parma
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonino Musolino
Phone
00300521702660
Email
antonino.musolino@unipr.it
Facility Name
Fondazione IRCCS Policlinico San Matteo
City
Pavia
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elisa Ferraris
Phone
0382503689
Email
e.ferraris@smatteo.pv.it
Facility Name
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
City
Roma
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emilio Bria
Phone
+390630155202
Email
emiliobria@yahoo.it; emilio.bria@policlinicogemelli.it
Facility Name
Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
City
Verona
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elena Fiorio
Phone
0458122769
Email
elena.fiorio@aovr.veneto.it; veronica.parolin@aovr.veneto.it;
Facility Name
National Cancer Center
City
Gyeonggi-do
Country
Korea, Republic of
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Keun Seok Lee
Email
kslee@ncc.re.kr
Facility Name
Asan Medical Center
City
Seoul
Country
Korea, Republic of
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sung-Bae Kim
Phone
82-2-3010-3217
Email
sbkim3@amc.seoul.kr
Facility Name
Korea University Anam Hospital
City
Seoul
Country
Korea, Republic of
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kyong Hwa Park
Phone
82-2-920-6841
Email
khpark@korea.ac.kr
Facility Name
Severance Hospital, Yonsei University Health System
City
Seoul
Country
Korea, Republic of
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joo Hyuk Sohn
Phone
82-2-2228-8135
Email
oncosohn@yuhs.ac
Facility Name
KO - MED Centra Kliniczne Sp. z o.o., Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej
City
Biała Podlaska
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Pawlowicz
Phone
+48 83 414 76 52
Email
maria.pawlowicz@szpitalbp.pl
Facility Name
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
City
Gdańsk
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacek Jassem
Phone
0048 58 349 2 270
Email
jjassem@gumed.edu.pl
Facility Name
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii
City
Gliwice
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michal Jarzab
Phone
48 32 2788721
Email
michal.jarzab@io.gliwice.pl
Facility Name
Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Klinika Onkologii Klinicznej
City
Kielce
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pawel Sidel
Phone
+48 41 36 74 808
Email
Pawel.Sidel@onkol.kielce.pl
Facility Name
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie - Oddzial Onkologii Klinicznej z Pododdzialem Dziennym
City
Krakow
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Kowalczyk-Tekiela
Phone
+48 502 315 790
Email
atekiela@interia.pl
Facility Name
SP ZOZ Szpital Uniwersytecki w Krakowie, Oddzial Onkologii Klinicznej
City
Kraków
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Piotr Wysocki
Phone
48 12 424-89-12
Email
piotr.wysocki@uj.edu.pl; klinikaonkologii@su.krakow.pl
Facility Name
NeuroMed
City
Lublin
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tomasz Jankowski
Phone
+48602405127
Email
tjankowski.onkolog@wp.pl
Facility Name
Uniwersytecki Szpital Kliniczny w Poznaniu, Oddzial Chemioterapii
City
Poznań
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rodryg Ramlau
Phone
+48513155613
Email
rramlau@gmail.com
Facility Name
Wielkopolskie Centrum Onkologii (WCO) / The Greater Poland Cancer Center
City
Poznań
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pawel Rozanowski
Phone
+48 61 88 50 736
Email
pawel.rozanowski@euromail.pl
Facility Name
Mazowiecki Szpital Onkologiczny
City
Wieliszew
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sylwina Socha
Phone
+48 22 766 15 00
Ext
134
Email
S.Socha@szpitalonkologiczny.pl
Facility Name
Instytut Centrum Zdrowia Matki Polki - Klinika Onkologii
City
Łódź
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ewa Kalinka
Phone
+48 42 271 11 07
Email
ewakalinka@wp.pl
Facility Name
Centrul Medical Focus
City
Bucharest
Country
Romania
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ingrid Iordan
Phone
0721298677
Email
mireliordan@yahoo.com
Facility Name
Filantropia Clinical Hospital
City
Bucharest
Country
Romania
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dragos Median
Phone
+40 744 874350
Email
dragos.median@gmail.com
Facility Name
Radiotherapy Center Cluj
City
Cluj-Napoca
Country
Romania
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrei Ungureanu
Phone
+40742206212
Email
andreiungureanu.oncolog@yahoo.com
Facility Name
Onco Clinic Consult SA
City
Craiova
Country
Romania
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patricia Visan
Phone
(+40) 724280084
Email
p.visan@oncoclinic.ro
Facility Name
Oncology Center Sfantul Nectarie
City
Craiova
Country
Romania
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Schenker
Phone
+40351401336
Email
mike_scheker@yahoo.com
Facility Name
Gral Medical SRL
City
Piteşti
Country
Romania
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adela-Luiza Chirila
Phone
+40766442720
Email
dr.adela_chirila@yahoo.com
Facility Name
OncoMed Oncology Center
City
Timişoara
Country
Romania
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniela Sirbu
Phone
+40 0744571617
Email
desirbu@yahoo.com
Facility Name
Hospital Clinic Barcelona
City
Barcelona
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tomas Pascual
Email
topascual@clinic.cat
Facility Name
Hospital Universitario Vall d'Hebron
City
Barcelona
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Meritxell Bellet
Phone
+34932746000
Email
mbellet@vhio.net
Facility Name
Hospital Universitario Reina Sofia
City
Córdoba
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Juan de la Haba
Email
juahaba@gmail.com
Facility Name
Clinica Universidad de Navarra - Madrid
City
Madrid
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jaime Espinos Jimenez
Email
jespinos@unav.es
Facility Name
Hospital General Universitario Gregorio Maranon
City
Madrid
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Lopez- Tarruella Cobo
Email
slopeztarruella@gmail.com
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eva Ciruelos Gil
Phone
0034913 90 80 00
Email
eva.ciruelos@gmail.com
Facility Name
Hospital Universitario de La Princesa
City
Madrid
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ana Isabel Ballesteros
Phone
+34915202200
Email
oncologiamedica.princesa@outlook.com
Facility Name
Hospital Regional Universitario de Malaga
City
Málaga
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ana Godoy Ortiz
Email
anagodort@gmail.com
Facility Name
Clinica Universidad de Navarra - Pamplona
City
Pamplona
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jaime Espinos Jimenez
Email
jespinos@unav.es
Facility Name
Instituto Valenciano de Oncologia
City
Valencia
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angel Guerrero Zotano
Phone
+34 96 111 4051
Email
aguerrero@fivo.org
Facility Name
Changhua Christian Hospital (CCH)
City
Changhua
Country
Taiwan
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shou-Tung Chen
Email
1886@cch.org.tw
Facility Name
Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
City
Kaohsiung
Country
Taiwan
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ming-Feng Hou
Email
mifeho@kmu.edu.tw
Facility Name
National Cheng Kung University Hospital
City
Tainan
Country
Taiwan
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei-Pang Chung
Phone
+886975014242
Email
edgarbun@gmail.com
Facility Name
Tri-Service General Hospital
City
Taipei City
Country
Taiwan
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ming-Shen Dai
Phone
+886-2-87927208
Email
dms1201@gmail.com
Facility Name
Koo Foundation Sun Yat-Sen Cancer Center
City
Taipei
Country
Taiwan
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chi-Feng Chung
Email
cheh@kfsyscc.org
Facility Name
National Taiwan University Hospital
City
Taipei
Country
Taiwan
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chiun-Sheng Huang
Email
huangcs@ntu.edu.tw
Facility Name
Linkou Chang Gung Memorial Hospital (CGMHLK)
City
Taoyuan City
Country
Taiwan
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shin-Cheh Chen
Email
chensc@cgmh.org.tw
Facility Name
Trakya University Medical Faculty
City
Merkez
State/Province
Edirne
Country
Turkey
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Irfan Cicin
Phone
0532 248 09 88
Email
irfancicin@hotmail.com
Facility Name
Kocaeli University Faculty of Medicine
City
İzmit
State/Province
Kocaeli
Country
Turkey
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Devrim Cabuk
Email
devrim.cabuk@kocaeli.edu.tr
Facility Name
Ankara University Medical Faculty Medical Oncology Department
City
Ankara
Country
Turkey
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuksel Urun
Phone
00905337483275
Email
dr.yukselurun@gmail.com
Facility Name
Uludag University Medical Faculty
City
Bursa
Country
Turkey
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Turkkan Evrensel
Phone
00905336460546
Email
evrensel@uludag.edu.tr
Facility Name
Liv Hospital Ankara
City
Cankaya
Country
Turkey
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Saadettin Kilickap
Email
skilickap@yahoo.com
Facility Name
Goztepe Prof. Dr. Suleyman Yalcin City Hospital
City
Istanbul
Country
Turkey
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mahmu Gumus
Phone
+90 5063509061
Email
mgumus@superonline.com
Facility Name
Medical Point Izmir Hospital
City
İzmir
Country
Turkey
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cagatay Arslan
Phone
+905052642353
Email
arslancagatay@yahoo.com
Facility Name
Suat Seren Training and Research Hospital
City
İzmir
Country
Turkey
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sema Erturk
Facility Name
West Middlesex University Hospital
City
Isleworth
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pippa Riddle
Phone
02083216781
Email
pippa.riddle@nhs.net
Facility Name
Leeds Teaching Hospitals NHS Trust
City
Leeds
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chris Twelves
Email
C.J.Twelves@leeds.ac.uk
Facility Name
The Christie NHS Foundation Trust
City
Manchester
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Armstrong
Facility Name
Nottingham City Hospital
City
Nottingham
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah Khan
Facility Name
Lancashire Teaching Hospitals
City
Preston
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Hogg
Email
martin.hogg@lthtr.nhs.uk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

We'll reach out to this number within 24 hrs